DoW Peer Reviewed Cancer, Clinical Trial Award
- Posted
- May 6, 2026
- Closed
- October 5, 2026
- Program funding
- $45,000,000
- Expected awards
- 10
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 12.420
- Archives
- November 4, 2026
Program funding history
Awards made under Assistance Listing 12.420 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $1.3B
- FY2026 obligated
- $598.5M
- FY2027 (to date) obligated
- $0
- Awards in window
- 4,414
Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Regents of the University of California, San Francisco, the, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Distinctive Features:
• Applications to this award mechanism must include a clinical trial.
• Projects can range from phase 0 to phase III.
• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.
• Applications are required to include patient advocates.
• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Who can apply
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- DoW Traumatic Brain Injury and Psychological Health, Clinical Trial Award
- DoW Autism Clinical Trial Award
- DoW Vision, Clinical Trial Award
- DoW Spinal Cord Injury, Clinical Trial Award
- DoW Breast Cancer, Clinical Research Extension Award
- DoW Toxic Exposures Clinical Trial Award
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing